Skip to content
Open access

A multiancestry polygenic risk score for Alzheimer’s disease is associated with cognitive decline and neuropathological hallmarks in diverse populations

Aug 2026 · Nature Genetics · Vol 58, pp. 2141 - 2151 · 0 citations · 123 references
Medicine

TL;DR

An APOE-independent polygenic risk score for Alzheimer’s disease derived from multiancestry GWAS summary statistics shows consistent associations with cognitive, imaging, biomarker and neuropathological features in diverse populations.

Abstract

Previously derived polygenic risk scores (PRSs) for Alzheimer’s disease (AD) perform inconsistently across diverse ancestries. We developed an APOE-independent multiancestry AD PRS using genome-wide association study summary statistics applied to European ancestry, African American, Caribbean Hispanic and East Asian cohorts. PRS performance was evaluated in a large independent multiancestry dataset and validated in several additional multiancestry cohorts. The PRS was significantly associated with AD in European ancestry, African American, Caribbean Hispanic and Native American Hispanic groups with adjusted odds ratios between 1.14 and 1.52 per PRS standard deviation. PRS performance was validated in the replication cohorts (odds ratios: 1.21–1.65). The PRS was also associated with poorer memory, executive function and language performance, greater AD-related neuropathological burden, reduced hippocampal volume, lower cerebrospinal fluid amyloid-β42 and elevated total tau and phosphorylated tau, with stronger phosphorylated tau associations observed in women. Our findings support the value of ancestry-aware PRSs as a component of broader multimodal risk stratification frameworks. An APOE-independent polygenic risk score for Alzheimer’s disease derived from multiancestry GWAS summary statistics shows consistent associations with cognitive, imaging, biomarker and neuropathological features in diverse populations.

Read PDF

Similar papers

Open access Aug 2026

Predictive value of the Alzheimer polygenic risk score on cognitive decline in patients with mild cognitive impairment and Alzheimer's disease dementia

Although polygenic burden contributes to variability in cognitive trajectories, its added predictive value beyond routinely available clinical variables remains modest.

B. Calm, Adrián Hinojosa-Calleja, F. García-Gutiérrez et al. · 0 citations
Open access Sep 2026

Alzheimer’s Polygenic Risk Scores Are Not Interchangeable: Evidence from 1,752 Models

Introduction: Polygenic risk scores (PRS) may improve Alzheimer's disease (AD) risk prediction before symptom onset, yet choosing an appropriate model can be challenging. Methods: Using the standardized GenoPred pipeline, 1,752 PRS models (9 algorithms; 584 configurations; 3 genome-wide association studies) were evalua...

Elizabeth L. Ward, Peter T. Nelson, Y. Katsumata et al. · 0 citations
Open access Sep 2026

Rare extreme polygenic risk scores strongly indicate Alzheimer’s disease risk

Background. Alzheimer's disease (AD) pathology often accumulates years before memory loss, creating a need to identify high-risk individuals presymptomatically. Polygenic risk scores (PRS) stratify AD risk, but individual-level predictions remain uncertain. Extreme PRS may identify high-risk individuals independent of...

Elizabeth L. Ward, Peter T. Nelson, Y. Katsumata et al. · 0 citations
Open access Oct 2026

Potential association between dementia polygenic risk scores and subjective cognitive burden in a post-COVID cohort: a hypothesis-generating study

Coronavirus disease 2019 (COVID-19) may be associated with persistent subjective cognitive complaints, including difficulties with attention, memory, and executive function, in some individuals with post-acute sequelae of SARS-CoV-2 infection (PASC, “long COVID”). Inter-individual variability raises the possibility...

Aleemah Nasif, Punya Sunil, Ranajit Das · 0 citations
Open access 2026

Associating a Polygenic Risk Score for Multiple Sclerosis with Brain MRI Metrics and Cognitive Performance in Healthy UK Biobank Participants.

In neurologically healthy individuals, a higher genetic burden for MS was associated with slower information processing speed in the highest-risk subgroup and with altered WM microstructure in the splenium of the corpus callosum.

Chen-Yue Feng, J. Kikuta, A. Hagiwara et al. · 0 citations
Open access Sep 2026

Plasma P-tau217, APOE Genotype, and the Timing of Cognitive Impairment in individuals Across Diverse Racial and Ethnic Groups: A Pooled Analysis of Prospective Cohort Studies

Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.

Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.